54439-75-7

Usage

Uses

Used in Organic Synthesis:
2-Chloro-4-hydroxybenzaldehyde 98% is utilized as an intermediate in the production of various pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a key component in the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Chloro-4-hydroxybenzaldehyde 98% serves as a building block for the synthesis of aromatic compounds that have potential therapeutic applications. Its role in creating new drug candidates is crucial for advancing medical treatments.
Used in Agrochemical Production:
2-Chloro-4-hydroxybenzaldehyde 98% is also employed in the development of agrochemicals, contributing to the creation of compounds that can be used in agriculture for pest control and crop protection.
Safety and Storage:
Due to its chemical properties, 2-Chloro-4-hydroxybenzaldehyde 98% should be handled with care to prevent any adverse reactions. It is recommended to store 2-Chloro-4-hydroxybenzaldehyde 98% in a cool, dry place, away from direct sunlight and heat sources, to maintain its stability and purity.

InChI:InChI=1/C8H7ClO2/c1-11-7-3-2-6(5-10)8(9)4-7/h2-5H,1H3

Upstream product

• 74-90-8 hydrogen cyanide 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 42533-63-1 1-(bromomethyl)-2-chloro-4-nitrobenzene 
• 74-88-4 methyl iodide 
• 108-43-0 3-monochlorophenol 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 121-86-8 2-chloro-4-nitrotoluene 
• 123-11-5 4-methoxy-benzaldehyde 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 5568-33-2 2-chloro-4-nitrobenzaldehyde 
• 124-41-4 sodium methylate 

Downstream Products

• 334018-24-5 (2-chloro-4-methoxyphenyl)methanol 
• 441060-97-5 1-(2,2-dibromoethenyl)-2-chloro-4-methoxybenzene 
• 1001441-61-7 3-(2-chloro-4-methoxyphenyl)-1-(4-methoxyphenyl)propenone 
• 1079352-25-2 5-(1-methylpropyl)-2-(2-chloro-4-methoxyphenyl)-3,7-dimethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 
• 1433946-20-3 C₃₄H₂₆Cl₂N₂O₄ 
• 1433946-21-4 C₃₄H₂₈Cl₂N₂O₄ 
• 1079359-27-5 2-(2-chloro-4-methoxyphenyl)-5-(1-ethylpropyl)-7-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 
• 941696-23-7 6-bromo-2-(2-chloro-4-methoxyphenyl)-1,4-dimethyl-1H-benzimidazole 
• 663944-60-3 2,2'-dichloro-4,4'-dimethoxybenzil 
• 935750-36-0 2-(2-chloro-4-methoxyphenyl)-1,4-bis(4-methoxyphenyl)-5-phenyl-1H-imidazole 
• 935750-30-4 2,4-bis(2-chloro-4-methoxyphenyl)-1-(4-methoxyphenyl)-5-methyl-1H-imidazole 
• 935750-31-5 2-(2-chloro-4-methoxyphenyl)-5-ethyl-1,4-bis(4-methoxyphenyl)-1H-imidazole 
• 935750-28-0 2-(2-chloro-4-methoxyphenyl)-1,4-bis(4-methoxyphenyl)-5-methyl-1H-imidazole 

Relevant academic research and scientific papers

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D

Cyclic sulfamidates as versatile lactam precursors. An evaluation of synthetic strategies towards (-)-aphanorphine

A full account of studies which led to the efficient asymmetric synthesis of (-)-aphanorphine 1 is reported. Two routes to the key cyclic sulfamidate intermediate 5 are described, the first was based on a chiral auxiliary approach and the second utilised

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Heterocyclic compounds

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Y1 and Y2 are nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT

Tri- heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1 is alkyl, alkenyl,

PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

A compound of the formula wherein R1 is a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 nitrogen atom(s), which heterocycle is attached by a secondary nitrogen atom constituting the heterocycle; X is an oxygen atom, a nitrogen atom optionally substituted by a hydrocarbon group having 1 to 5 carbon atom(s) or a sulfur atom optionally oxidized with 1 or 2 oxygen, Y is a bond or a C1-5 alkylene group, R2 is (1) a hydrogen atom, (2) a hydroxy group, (3) a C1-5 alkoxy group, (4) a C1-5 alkylthio group, (5) a carbocycle having 3 to 15 carbon atoms or (6) a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s), provided that when Y is a bond, R2 is a carbocycle having 3 to 15 carbon atoms or a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s) and; one of R3 and R4 is a hydrogen atom or a group of the formula: -Z-R5 (Z is a bond or C1-10 alkylene group optionally having substituent(s) and R5 is (1) a hydrogen atom, (2) a hydroxy group, (3) a C1-5 alkoxy group, (4) a nitrile group, (5) a C1-5 alkoxy-carbonyl group, (6) a carboxyl group, (7) a carbamoyl group, (8) a (mono or di-C1-5 alkyl)carbamoyl group, (9) an amino group, (10) a (di or mono-C1-5 alkyl)amino group, (11) a (C1-5 alkoxy-carbonyl)amino group, (12) a C1-5 alkylthio group, (13) a carbocycle having 3 to 15 carbon atoms or (14) a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s)); the other is a group of the formula: -Z-R5 (Z and R5 are as defined above); and R3 and R4 may form, together with the adjacent nitrogen atom, a heterocycle having a skeleton consisting of 3 to 15 atoms, which heterocycle is attached by a secondary nitrogen atom constituting the heterocycle, wherein the above-mentioned heterocycle and a carbocycle having 3 to 15 carbon atoms are each optionally substituted by substituent(s) selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C7-16 aralkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-14 aryl, C1-8 alkoxy, C1-3 alkylenedioxy, hydroxy, halogen atom, amino, (di or mono-C1-5 alkyl)amino, (C1-5 alkoxy-carbonyl)amino, (C1-5 acyl)amino, (C1-5 acyl) (C1-5 alkyl)amino, C1-5 alkylthio, nitrile, nitro, C1-5 alkoxy-carbonyl, carboxyl, C1-5 alkyl-carbonyloxy, oxo, thioxo, C1-6 acyl group, sulfamoyl and (di or mono-C1-5 alkyl)sulfamoyl, or a salt thereof or a prodrug thereof have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the prophylaxis or treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis and the like, allergic diseases such as asthma, or disorders of male or female genital function and the like.

Ring-Substituted y1,2-Bis(4-hydroxyphenyl)ethylenediamine>dichloroplatinum(II) Complexes: Compounds with a Selective Effect on the Hormone-Dependent Mammary Carcinoma

dichloroplatinum(II) complexes with one substituent in the 2-position (CH3, CF3, F, Br, I: meso- and dl-1-PtCl2, meso-(3-5)-PtCl2, meso-(7 and 8)-PtCl2) or two substituents in the 2,6-position (CH3, Cl: meso-2-PtCl2, meso- and dl-6-PtCl2) in both benzene rings were synthesized and tested for estrogenic and toxic activities.Two complexes (meso-6-PtCl2 and meso-7-PtCl2) possess both effects.In comparative tests on estrogen receptor positive and negative mammary tumors in cell culture (MCF 7, ER+ and MDA-MB 231, ER-) and in animals (MXT, ER+ and MXT, ER-, mouse), meso-6-PtCl2 shows a selective effect on the estrogen receptor positive mammary carcinoma.A further increase of efficacy was achieved with the water-soluble (sulfato)platinum(II) derivative (meso-6-PtSO4).On the DMBA-induced hormone dependent mammary carcinoma of the SD rat, meso-6-PtSO4 is significantly more active than its ligand (meso-6) and cisplatin.